Vertex Pharmaceuticals stock
Price history
+23.95% over the period1 year: from $434.52 (November 13, 2025) to $538.60 (November 13, 2026), +23.95%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $538.60 |
| October 30, 2026 | $558.88 |
| September 30, 2026 | $522.81 |
| August 31, 2026 | $544.52 |
| July 31, 2026 | $477.10 |
| June 30, 2026 | $496.73 |
| May 29, 2026 | $447.54 |
| April 30, 2026 | $427.38 |
| March 31, 2026 | $446.54 |
| February 27, 2026 | $496.83 |
| January 30, 2026 | $469.90 |
| December 31, 2025 | $453.36 |
| November 28, 2025 | $433.61 |
| November 13, 2025 | $434.52 |
At a glance
The company
Biotechnology company developing transformative medicines for serious diseases including cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain
Latest results
Quarter to September 30, 2026 · EPS $4.76 (estimate $4.76)
TickerLandia's take on Vertex Pharmaceuticals
- Pricier than usual relative to earnings: P/E on the latest fiscal year 35 vs a median of 27 over its last 8 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 35 vs 35 (+0%) in a group of 7.
- Strong point: Market momentum (70/100 in its group). Weak point: Growth (31/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−5.29% from the 52-week high
Analysts · 32 analysts
Average target$595.36+10.54% vs. price
Buy 26 · Hold 5 · Sell 1 · Buy
TickerLandia Fingerprint: Vertex Pharmaceuticals
Compared with similar companies: low risk, strong momentum, and high profitability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage52
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 34.7 42 EV/EBITDA 26.8 59 Forward P/E 27.0 46 Price/sales 10.5 57 Price/book 6.53 56 Profitabilityhigh69
How much it earns on revenue and capital.
Metric Value Position in group ROA 10.6% 81 Operating margin 37.8% 84 Net margin 30.7% 78 ROE 20.8% 72 Gross margin 54.8% 32 Earnings stabilityaverage59
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 19.4% 56 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 62 Growthlow31
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +10.35% 25 Revenue growth (year over year) +11.80% 32 Earnings growth (year over year) −39.00% 35 Financial strengthaverage54
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.63 64 Interest coverage 352.4 90 Debt/equitycounts in reverse: lower means more financial strength 0.31 34 Current ratio 2.34 27 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong70
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +7.56% 68 Relative strength (6 months) +17.03% 75 1-year return +23.95% 66 Distance from 200-day average +11.43% 72 Risklow25
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 15.2% 11 Beta (1 year) 0.44 38 Volatility (60 days) 25.7% 27
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Vertex Pharmaceuticals is pricier than in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Vertex Pharmaceuticals's P/E today is 35.2, above the median of its last 8 fiscal years (26.8; between 20.5 and 144.1 from 2017 to 2025). Vertex Pharmaceuticals's P/E (trailing 12 months): 34.7, in line with the median of a group of 7 similar companies (34.7).
Compared with 7 similar companies
| Metric | Vertex Pharmaceuticals | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 34.7 | Middle | |
| Forward P/E | 27.0 | Middle | |
| Operating margin | 37.8% | High | |
| ROE | 20.8% | High | |
| Debt/equity | 0.31 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Vertex Pharmaceuticals. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$3.44B
Latest quarter · Q3 2026
Net income
$653.6M
Latest quarter · Q3 2026
Quarterly net margin
19.0%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $136.56B
- P/E
- 34.7
- EPS
- $15.54
- Volume
- 750.53K
- Daily trading
- €754.15M
- Dividend yield
- 0.00%
How Vertex Pharmaceuticals is changing
All resultsRevenue grew 14.1% a year on average over the last 5 years
Operating margin fell from 48.2% to 34.8%
Free cash flow equal to 82% of net income
Returns
Vertex Pharmaceuticals returns
$1,000 invested in Vertex Pharmaceuticals 5 years ago, on November 15, 2021, would be worth $2,882 today: +188.24% in total, +23.61% per year. This is the price return only: dividends are excluded.
| Period | Vertex Pharmaceuticals | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +11.00% | −3.12% | $1,110 |
| 6 months | +18.88% | +1.58% | $1,189 |
| Year to date | +18.80% | +10.46% | $1,188 |
| 1 year | +23.95% | +12.23% | $1,240 |
| 3 years | +42.14% | +71.41% | $1,421 |
| 5 years | +188.24% | +61.48% | $2,882 |
| 10 years | +470.43% | +249.40% | $5,704 |
Over the last 6 months it has done better than 53% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Vertex Pharmaceuticals: technical analysis
Vertex Pharmaceuticals is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 3.6% below its all-time closing high ($558.88, October 30, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 53
- Between 30 and 70
- vs 200-session average
- +11.43%
Support and resistance
Price areas where Vertex Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$557.97+3.60%2 touches, last on September 3, 2026
- Last price$538.60
- Support$531.78−1.27%2 touches, last on September 28, 2026
- Support$498.54−7.44%5 touches, last on October 5, 2026
- Support$485.53−9.85%3 touches, last on October 13, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.44
- Volatility (60 sessions, annualised)
- 25.7%
- Largest fall in the last year
- −15.21%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Vertex Pharmaceuticals: seasonality
Average monthly price change over 36 years
Over the last 36 years, the strongest month for Vertex Pharmaceuticals has been May: +7.69% on average, positive in 20 years out of 35. The weakest has been March: −2.20% on average, positive in 15 years out of 35. November, the current month, has been positive in 17 years out of 35 (−2.03% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.44% | +3.70% | 23 of 35 |
| February | +0.16% | −1.13% | 16 of 35 |
| March | −2.20% | −1.84% | 15 of 35 |
| April | +1.63% | +3.13% | 21 of 35 |
| May | +7.69% | +4.06% | 20 of 35 |
| June | +3.18% | +0.90% | 20 of 35 |
| July | −0.65% | −0.25% | 16 of 35 |
| August | +4.89% | +2.70% | 23 of 36 |
| September | +2.83% | −0.38% | 17 of 36 |
| October | +0.28% | +1.87% | 20 of 36 |
| November | −2.03% | −1.33% | 17 of 35 |
| December | +7.16% | +5.73% | 23 of 35 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Vertex Pharmaceuticals and its competitors
Sales reach patients in the United States, Europe and other countries, with the United States accounting for 62.9% of revenue, Europe for 28.8% and the rest of the world for 8.3%. The biotechnology company offers cystic fibrosis medicines such as TRIKAFTA/KAFTRIO, ORKAMBI and KALYDECO, as well as CASGEVY for sickle cell disease and transfusion dependent beta thalassemia, and JOURNAVX for acute pain in adults. Its pipeline includes candidates for APOL1-mediated kidney disease, type 1 diabetes and myotonic dystrophy type 1. Customers include specialty pharmacies, distributors, wholesalers, retail pharmacies, hospitals and clinics.
- Headquarters
- Boston, United States
- Employees
- 6,400
- Founded
- 1989
- Chief executive
- Reshma Kewalramani
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Vertex PharmaceuticalsVRTX | $136.56B | 37.8% | 34.7 | +18.88% |
| Regeneron PharmaceuticalsREGN | $98.84B | 30.4% | 21.1 | +32.73% |
| ModernaMRNA | $90.38B | -80.8% | — | +343.02% |
| argenxARGX | $60.37B | 31.9% | 33.3 | +19.60% |
| BeOne MedicinesONC | $47.58B | 17.8% | 53.4 | +31.59% |
| Royalty PharmaRPRX | $39.85B | 64.4% | 45.3 | +30.16% |
Same industry or related industries, similar size. Compare Vertex Pharmaceuticals with its competitors · Full profile
More on Vertex Pharmaceuticals
- Vertex Pharmaceuticals revenue and financials
- Vertex Pharmaceuticals valuation
- Vertex Pharmaceuticals stock return
- Vertex Pharmaceuticals employees, headquarters and business
